Rhumbline Advisers Capricor Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 46,083 shares of CAPR stock, worth $670,968. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,083
Previous 31,914
44.4%
Holding current value
$670,968
Previous $485,000
31.55%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CAPR
# of Institutions
100Shares Held
8.55MCall Options Held
1.78MPut Options Held
1.4M-
Black Rock Inc. New York, NY1.63MShares$23.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$23 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA638KShares$9.29 Million0.0% of portfolio
-
State Street Corp Boston, MA512KShares$7.46 Million0.0% of portfolio
-
Superstring Capital Management LP New York, NY337KShares$4.91 Million4.49% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $354M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...